Lupin's Q3 FY 2025-26 Quarterly Results
- 13 Feb 2026
Result Summary
- Lupin Ltd reported a 2.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 25.1%.
- Its expenses for the quarter were up by 4.0% QoQ and 12.3% YoY.
- The net profit decreased 20.5% QoQ and increased 37.5% YoY.
- The earnings per share (EPS) of Lupin Ltd stood at 25.67 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 7282.22 | 7137.51 | 5821.42 | 2.0% | 25.1% |
Total Expenses | 5333.61 | 5130.54 | 4750.15 | 4.0% | 12.3% |
Profit Before Tax | 1522.04 | 2006.97 | 1071.27 | -24.2% | 42.1% |
Tax | 341.53 | 522.14 | 212.41 | -34.6% | 60.8% |
Profit After Tax | 1180.51 | 1484.83 | 858.86 | -20.5% | 37.5% |
Earnings Per Share | 25.67 | 32.28 | 18.69 | -20.5% | 37.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Lupin Ltd is a major pharmaceutical company known for producing a diverse array of medications, including branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company operates primarily in the pharmaceutical industry, where it focuses on advancing healthcare through its innovation-driven approach. Lupin's commitment to high-quality standards and extensive research and development efforts has positioned it as a significant player in the global pharmaceutical market. As of the latest data available, there have been no specific recent developments provided for Lupin Ltd.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), Lupin Ltd reported a total income of ₹7282.22 crores, a 2.0% increase quarter-over-quarter (QoQ) from ₹7137.51 crores in Q2FY26, and a 25.1% increase year-over-year (YoY) from ₹5821.42 crores in Q3FY25. The growth in revenue reflects the company's continued expansion in its core pharmaceutical business, possibly indicating an increased demand for its products or successful market penetration strategies.
Profitability
Lupin Ltd's profitability for Q3FY26 showed a significant change compared to previous periods. The Profit Before Tax (PBT) decreased by 24.2% QoQ from ₹2006.97 crores in Q2FY26 to ₹1522.04 crores in Q3FY26, but increased by 42.1% YoY from ₹1071.27 crores in Q3FY25. The profit after tax (PAT) for Q3FY26 was ₹1180.51 crores, a 20.5% decrease QoQ from ₹1484.83 crores in Q2FY26, but a 37.5% increase YoY from ₹858.86 crores in Q3FY25. The Earnings Per Share (EPS) followed a similar pattern, decreasing by 20.5% QoQ to ₹25.67 from ₹32.28, yet rising by 37.3% YoY from ₹18.69. The tax expense was ₹341.53 crores for Q3FY26, marking a reduction of 34.6% QoQ from ₹522.14 crores, but an increase of 60.8% YoY from ₹212.41 crores.
Operating Metrics
Total expenses for Q3FY26 amounted to ₹5333.61 crores, which represented a 4.0% increase QoQ from ₹5130.54 crores in Q2FY26, and a 12.3% increase YoY from ₹4750.15 crores in Q3FY25. The increase in expenses could be associated with factors such as heightened production costs or strategic investments in research and development. The outlined financial data does not provide specific figures for additional ratios such as the P/E ratio, debt-to-equity ratio, or current ratio, making it challenging to conduct a detailed financial ratio analysis based solely on the provided information.